Thus, targeting Akt could offer a dual therapeutic benefit by preventing FLNA phosphorylation and restoring DLC1 activity, suggesting that Akt inhibitors such as MK-2206 could represent promising therapeutic agents for HCC treatment. This evidence concerns the gene DLC1 and hepatocellular carcinoma.